<Page>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
September 25, 2001
Date of Report
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-1136 22-079-0350
(Commission File Number) (IRS Employer Identification Number)
345 Park Avenue, New York, NY 10154
(Address of principal executive offices) (Zip Code)
(212) 546-4000
<Page>
Item 5. OTHER EVENTS
Incorporated by reference in its entirety is a press release issued by
the registrant on September 25, 2001, attached as exhibit 99.1, concerning the
registrant's announcement that it expects to re-file its New Drug Application
(NDA) with the U.S. Food and Drug Administration (FDA) for VANLEV(R).
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements
Inapplicable.
(b) Pro Forma Financial Information
Inapplicable.
(c) Exhibit.
99.1 Press Release dated September 25, 2001.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BRISTOL-MYERS SQUIBB COMPANY
By: /s/ Sandra Leung
-------------------------------
Name: Sandra Leung
Title: Corporate Secretary
<Page>
EXHIBIT INDEX
<Table>
<Caption>
Exhibit No. Description of the Exhibit
----------- --------------------------
99.1 Press Release dated September 25, 2001
</Table>